Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

China, licensing agreement with 3SBio, granting Pfizer exclusive rights for the development, manufacturing and commercialization of 3SBio’s SSGJ-707, a bispecific antibody targeting PD-1 and VEGF ...

Northeastern Chinese company 3SBio to receive $1.25B, in addition to $100M equity investment, $150M for exclusive rights in ...

HONG KONG, Aug. 24, 2023 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today released its 2023 interim results. Revenue in the first half of 2023 reached approximately ...

3SBio also launched Cipterbin (inetetamab) in 2020 and was covered under the National Reimbursement Drug List, or NRDL, the same year. This is an analog of Roche’s anti-HER2 mAb Herceptin.

Pfizer secrued exclusive global rights to 3SBio's cancer treatment candidate. It is a a licensing deal that could be worth $6.05 billion.

3SBio has good financial health. As of 2020, total debt was CNY 3 billion, net debt was minus CNY 218 million, and net debt to equity was negative 2%. The company generates approximately CNY 1 ...

The positions in the table below reflect the 3SBio's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position links to the ...

3SBio (HK: 1530) of Shenyang expanded its biosimilar business by raising its stake in Shanghai CP Guojian Pharma to 54%. 3SBio, which acquired 7% of Guojian last year, paid $213 million for 47% of ...